A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying ...

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

Mural Oncology has agreed to be acquired by biotechnology royalty aggregator XOMA Royalty in a deal worth up to $38.8 million. Mural on Wednesday said XOMA will pay an initial $2.035 a share in cash, ...

Clinical-stage California-based biotech Mural Oncology and XOMA Royalty Corporation , a biotechnology royalty aggregator have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly ...

Mural Oncology plc (NASDAQ: MURA), a clinical-stage immuno-oncology company, and XOMA Royalty Corporation (NASDAQ: XOMA), a biotechnology royalty aggregator, announced today they have entered into a ...

The average of price targets set by Wall Street analysts indicates a potential upside of 106.2% in XOMA Royalty (XOMA). While the effectiveness of this highly sought-after metric is questionable, the ...

Mural Oncology PLC (MURA) and XOMA Royalty Corporation (XOMA) announced on Wednesday that they have entered into a definitive ...

Mural Oncology Plc ( ($MURA) ) just unveiled an announcement. On August 20, 2025, Mural Oncology plc entered into a Transaction Agreement with ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mural Oncology plc (NASDAQ: MURA) to XOMA Royalty Corporation for $2.035 per share and, up to an additional $0.205 ...

We were pleased to advise XRA 5 Corp on its acquisition of Mural Oncology plc. XRA is a wholly owned subsidiary of XOMA ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...